Elisabetta Goio, Luca Ielasi, Francesca Benevento, Matteo Renzulli, Francesco Tovoli
{"title":"转移性肝细胞癌患者联合瑞非尼治疗和手术后的长期缓解。","authors":"Elisabetta Goio, Luca Ielasi, Francesca Benevento, Matteo Renzulli, Francesco Tovoli","doi":"10.2217/hep-2020-0014","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration.</p><p><strong>Patients & methods: </strong>We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.</p><p><strong>Results: </strong>A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.</p><p><strong>Conclusions: </strong>New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 3","pages":"HEP24"},"PeriodicalIF":1.2000,"publicationDate":"2020-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0014","citationCount":"4","resultStr":"{\"title\":\"Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.\",\"authors\":\"Elisabetta Goio, Luca Ielasi, Francesca Benevento, Matteo Renzulli, Francesco Tovoli\",\"doi\":\"10.2217/hep-2020-0014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration.</p><p><strong>Patients & methods: </strong>We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.</p><p><strong>Results: </strong>A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.</p><p><strong>Conclusions: </strong>New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.</p>\",\"PeriodicalId\":44854,\"journal\":{\"name\":\"Hepatic Oncology\",\"volume\":\"7 3\",\"pages\":\"HEP24\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2020-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/hep-2020-0014\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepatic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/hep-2020-0014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.
Aims: The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration.
Patients & methods: We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.
Results: A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.
Conclusions: New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.
期刊介绍：
Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
